Skip to main navigation

Now accepting applications for SPARK™ - Albireo’s Grants in Rare Liver Disease program. Learn more.

Clinical Trials
Partnerships
Media
Careers
Contact

Science & Medicine
Patients & Families
Responsibility
About Us
- Leadership
- Board of Directors
Investors

+

Science & Medicine
Patients & Families
Responsibility
About Us
Investors
Careers
Media
Contact

Press Releases

Year

March 1, 2022

Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update

February 22, 2022

Albireo to Report Q4 and Year-End 2021 Financial Results on March 1

February 22, 2022

NICE Recommends Albireo’s Bylvay® (odevixibat) for All PFIC Types

February 14, 2022

Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease

January 5, 2022

Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance

Pagination

First page
Previous page
Page 1
Current page 2

Email Alerts
RSS
Print

Site Map
Privacy Policy
Terms of Use
Cookie Settings
Contact

© 2022 Albireo Pharma, Inc